← All trials
NCT05544019
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Sep 16, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Schrödinger, Inc.Lead sponsor
Drugs studied
Indications studied
- Plasmablastic Lymphoma
- Burkitt Lymphoma
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Waldenstrom Macroglobulinemia
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Gene Rearrangement
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, B-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, B-Cell, Marginal Zone
- Herpesvirus 8, Human
- Lymphoma, Mantle-Cell
- Lymphoma, Primary Effusion
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.